BidaskClub cut shares of Editas Medicine (NASDAQ:EDIT) from a buy rating to a hold rating in a report issued on Thursday.
A number of other brokerages have also commented on EDIT. ValuEngine lowered shares of Editas Medicine from a hold rating to a sell rating in a research note on Friday, December 1st. Zacks Investment Research downgraded shares of Editas Medicine from a hold rating to a sell rating in a report on Tuesday, October 10th. Morgan Stanley reissued an equal weight rating and issued a $28.00 price objective (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Cann reissued a hold rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Cowen reissued a buy rating on shares of Editas Medicine in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $26.73.
Editas Medicine (NASDAQ:EDIT) opened at $24.96 on Thursday. Editas Medicine has a 52 week low of $13.12 and a 52 week high of $31.81. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19.
In other news, insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $23.64, for a total transaction of $196,992.12. Following the completion of the sale, the insider now owns 1,393,322 shares of the company’s stock, valued at approximately $32,938,132.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew A. F. Hack sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $25.35, for a total transaction of $126,750.00. Following the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $126,750. The disclosure for this sale can be found here. Insiders sold a total of 34,999 shares of company stock valued at $900,774 in the last three months. Insiders own 19.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP bought a new stake in shares of Editas Medicine during the 3rd quarter worth approximately $667,000. Granahan Investment Management Inc. MA lifted its holdings in shares of Editas Medicine by 7.1% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 241,719 shares of the company’s stock worth $5,804,000 after acquiring an additional 15,999 shares during the period. Allianz Asset Management GmbH bought a new stake in shares of Editas Medicine during the 3rd quarter worth approximately $3,263,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Editas Medicine by 18.6% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 117,012 shares of the company’s stock worth $2,810,000 after acquiring an additional 18,366 shares during the period. Finally, Greenwoods Asset Management Ltd lifted its holdings in shares of Editas Medicine by 156.3% during the 3rd quarter. Greenwoods Asset Management Ltd now owns 182,000 shares of the company’s stock worth $4,370,000 after acquiring an additional 111,000 shares during the period. 70.11% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/10/editas-medicine-edit-downgraded-by-bidaskclub.html.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.